Navepegritide

Navepegritide is a prodrug consisting of a 38-amino acid C-type natriuretic peptide (CNP) moiety conjugated to a multi-arm polyethylene glycol (PEG) carrier via a hydrolytically cleavable linker, developed by Ascendis Pharma under its proprietary TransCon technology platform. After subcutaneous injection, the PEG carrier is gradually cleaved in vivo, releasing active CNP at a sustained, steady rate over the course of the weekly dosing interval. This design avoids the peak-and-trough pharmacokinetic profile associated with shorter-acting CNP analogs and maintains continuous receptor engagement.

The released CNP binds with high affinity to natriuretic peptide receptor B (NPR-B) on chondrocytes residing in the growth plate cartilage. NPR-B is a guanylyl cyclase-linked receptor whose activation stimulates intracellular production of cyclic guanosine monophosphate (cGMP). Elevated cGMP activates protein kinase G type II (PKG-II), which phosphorylates the transcription factor CREB, upregulating cyclin D1 expression and thereby promoting chondrocyte proliferation and differentiation essential for endochondral ossification.

A second, therapeutically critical function of cGMP/PKG-II signaling is inhibition of the mitogen-activated protein kinase (MAPK) cascade at the level of Raf-1 kinase. This blocks fibroblast growth factor receptor 3 (FGFR3)-mediated ERK1/2 phosphorylation. In achondroplasia, a gain-of-function mutation in FGFR3 (most commonly G380R) constitutively over-activates the MAPK pathway, suppressing chondrocyte proliferation and shortening the hypertrophic zone of the growth plate. By counteracting this pathological FGFR3-MAPK signal, navepegritide restores more normal rates of endochondral bone elongation. The sustained CNP exposure provided by the TransCon prodrug strategy is designed to maintain this inhibition continuously throughout the dosing week.

The principal evidence base for navepegritide derives from the ApproaCH trial (NCT05598320), a phase 2b randomized, double-blind, placebo-controlled multicenter study conducted across 10 hospitals in Australia, Canada, Denmark, Ireland, New Zealand, Spain, and the United States. Eighty-four treatment-naive children aged 2 to 11 years with genetically confirmed achondroplasia were enrolled and randomized 2:1 to navepegritide 100 micrograms per kilogram weekly (n=57, mean age 5.6 years) or placebo (n=27, mean age 6.0 years) for 52 weeks. Results were published in JAMA Pediatrics in November 2025.

The primary endpoint, annualized growth velocity (AGV) at week 52, was met with high statistical significance. The navepegritide group achieved a mean AGV of 5.89 cm per year versus 4.41 cm per year for placebo, a least-squares mean treatment difference of 1.49 cm per year (95% CI 1.05 to 1.93; p less than 0.001). Age-stratified analysis showed a difference of 1.02 cm per year (p=0.0084) in children aged 2 to under 5 years and 1.78 cm per year (p less than 0.0001) in children aged 5 to 11 years. Secondary endpoints included improvements in achondroplasia-specific height z-scores, tibial-femoral angle (a measure of lower-limb alignment), and physical functioning scores. A 52-week open-label extension period provided up to 2 years of follow-up data submitted to the FDA.

On February 27, 2026, the FDA granted accelerated approval to navepegritide (brand name YUVIWEL) for increasing linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses. Accelerated approval was based on improvement in AGV as a reasonably likely surrogate endpoint; confirmatory trials to verify long-term clinical benefit remain ongoing.

An ongoing phase 2 open-label COACH trial (21 children, ages 2 to 11) evaluated weekly navepegritide plus weekly lonapegsomatropin (TransCon hGH). Week-52 data, reported in January 2026, showed mean AGV exceeding the 97th percentile for children of average stature, with improvements in body proportionality, arm span, lower-limb alignment, and spinal canal interpedicular distance, and without acceleration of bone age. This combination remains investigational and is not yet approved.

Navepegritide is approved for once-weekly subcutaneous injection in pediatric patients aged 2 years and older with achondroplasia and open epiphyses. Dosing is weight-based, targeting approximately 0.1 mg per kilogram per week (100 micrograms per kilogram per week). The prescribing information provides a fixed-dose table by weight band: doses range from 0.88 mg for patients weighing 8 to 9.9 kg up to 8.8 mg for patients weighing 73.6 to 90 kg. Doses are rounded to the nearest available vial strength.

The drug is supplied as lyophilized powder in single-dose vials of 1.3 mg, 2.8 mg, and 5.5 mg, each requiring reconstitution prior to injection. For patients exceeding 55.9 kg who require a volume greater than 1 mL, two separate injections at different sites are required.

Dosing flexibility: the weekly injection may be administered up to 2 days before or after the scheduled date, provided that a minimum interval of 5 days is maintained between doses. Healthcare providers should reassess body weight periodically and adjust the dose accordingly as children grow. Treatment should be discontinued upon evidence of epiphyseal closure.

The FDA label recommends against use in patients with moderate or severe renal impairment (eGFR below 60 mL per minute per 1.73 m squared). No formal dose adjustment guidance for hepatic impairment is provided. No contraindications are listed in the approved label.

This information is provided for educational purposes only and does not constitute medical advice. Dosing decisions should be made by a licensed healthcare provider in accordance with the full prescribing information and the individual patient's clinical circumstances.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The principal combination evaluated in controlled research is navepegritide paired with lonapegsomatropin (TransCon hGH, a once-weekly PEGylated human growth hormone prodrug also developed by Ascendis Pharma). The rationale is mechanistic complementarity: CNP promotes endochondral ossification via NPR-B and MAPK inhibition, while growth hormone acts primarily through the IGF-1 axis to stimulate chondrocyte proliferation and protein synthesis. These pathways are largely distinct, raising the hypothesis that combination therapy could produce additive or synergistic growth effects.

The phase 2 open-label COACH trial tested this combination in 21 children (two cohorts: treatment-naive, n=12; and previously treated with navepegritide monotherapy, n=9). Week-52 data showed mean AGV exceeding the 97th percentile for average stature children, improvements in arm span z-score, spinal canal dimensions, and tibial-femoral angle beyond those seen with navepegritide monotherapy, and no acceleration of bone age. This combination remains investigational; no regulatory approval for the combination as a fixed regimen has been granted as of the publication of this entry.

No other pharmacological combinations have been evaluated in controlled clinical trials for navepegritide. Any use alongside vosoritide (a daily CNP analog) would be pharmacodynamically duplicative and is not supported by evidence. Anecdotally, adjunctive use of growth-supportive nutritional or physical therapies alongside navepegritide follows standard achondroplasia multidisciplinary care guidelines but has not been formally studied in combination with the drug.

Navepegritide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

In the ApproaCH phase 2b trial, 91.2% of navepegritide-treated children and 96.3% of placebo recipients experienced at least one treatment-emergent adverse event (TEAE), and the overall rates were broadly similar between arms, with the majority of events being grade 1 or 2. No treatment-related serious adverse events, deaths, or symptomatic hypotension episodes were reported in the navepegritide group.

Adverse reactions occurring in 5% or more of navepegritide-treated patients in the pivotal trial or as reported in the prescribing information include vomiting (21%), injection-site reactions (19%), extremity pain (12%), and nausea (6%). Injection-site reactions encompassed transient swelling, erythema, bruising, pruritus, blistering, and discoloration; all were described as mild and self-limiting. Hypertrichosis (localized or generalized excess hair growth) was reported in approximately 3% of patients, a known class effect of natriuretic peptide analogs.

Common infections also reported in the trial included pyrexia (35.1%), nasopharyngitis (31.6%), otitis media (24.6%), upper respiratory tract infection (19.3%), and headache (17.5%), though many of these were considered intercurrent childhood illnesses rather than drug-related events.

The approved label carries a warning regarding risk of blood pressure reduction. Transient, asymptomatic decreases in blood pressure have been observed; patients and caregivers should be instructed to contact a provider if dizziness, unusual fatigue, or nausea occur. Patients with moderate or severe renal impairment (eGFR below 60 mL per minute per 1.73 m squared) are not recommended to receive navepegritide. No absolute contraindications are listed. The drug has not been studied in pregnant or lactating patients; use is limited to the pediatric indication. Long-term safety beyond two years of open-label extension data is not yet fully characterized.